Clinical Trials Logo

Filter by:
NCT ID: NCT06299852 Recruiting - Clinical trials for Oligometastatic Disease

Stereotactic Radiation Therapy for HE2-positive Oligometastatic Breast Cancer

Start date: July 1, 2022
Phase: N/A
Study type: Interventional

This study involves two non-randomized groups of patients: the observation group and the comparison group. The comparison group will retrospectively include data on 29 patients with oligometastatic HER2-positive breast cancer who received treatment with trastuzumab-emtansine and had a history of SRT. The prospective part of this study aims to include 29 patients with oligometastatic HER2-positive breast cancer. These patients will undergo SRT followed by the administration of trastuzumab emtansine 24 hours after the SRT. The combined effect of stereotactic radiation therapy on a metastatic lesion followed by anti-HER2 therapy in the 2nd line - trastuzumab emtansine, remains unexplored. This study plans to evaluate the effectiveness of combining systemic therapy and local control methods (SRT) in patients with oligometastatic HER2-positive breast cancer. It will be the first time the efficacy and toxic profile of this new combined treatment method in this patient population will be studied. This basket trial evaluates trastuzumab emtansine for oligo-metastatic breast cancer with the aim of inducing deep responses, long-lasting disease remissions, and potentially cure.

NCT ID: NCT06296732 Recruiting - Neuroblastoma Clinical Trials

Abdominal Neuroblastoma Laparoscopic Surgery Risk Factors Stratification

ANLAP-R
Start date: October 19, 2023
Phase:
Study type: Observational [Patient Registry]

Surgery plays significant role in treatment of neurogenic tumors, both for benign ganglioneuroma and for high risk neuroblastoma. The world literature has accumulated large experience in laparoscopic surgery for abdominal neuroblastoma. The presence of IDRF (image-defined risk factors) and tumor size (>4-7 cm) are considered as common contraindications for minimally invasive surgery in neuroblastoma. However, the recent studies have shown that presence of IDRF is not an absolute contraindication for laparoscopic surgery. This open-label, nonrandomized, observational, phase III evaluates role and weight of different surgical risk factors (including IDRF, tumor size, tumor localization, tumor volume/patient height ratio, previous open surgical procedures, previous chemotherapy etc.) in the laparoscopic neuroblastoma resections. The aim of this study is to create novel risk factors scoring system for laparoscopic surgery in abdominal neuroblastoma.

NCT ID: NCT06296121 Recruiting - Multiple Myeloma Clinical Trials

A Study of the Efficacy and Safety of Monotherapy With BCD-264 and Darzalex in Subjects With Relapsed and Refractory Multiple Myeloma

DARVIVA
Start date: December 21, 2023
Phase: Phase 3
Study type: Interventional

The aim of this study is to confirm the comparability of the efficacy and safety profiles of BCD-264 and Darzalex as monotherapy for relapsed and refractory multiple myeloma in subjects previously treated with proteasome inhibitors and immunomodulatory drugs, and who had disease progression on prior therapy.

NCT ID: NCT06292351 Recruiting - Alzheimer Disease Clinical Trials

DMB-I in the Treatment of Alzheimer Type Dementia

Start date: December 27, 2023
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to assess the efficacy and safety of DMB-I for the treatment of patients with Alzheimer type dementia.

NCT ID: NCT06288633 Recruiting - Bradycardia Clinical Trials

Cardioneuroablation for Bradyarrhythmia

CARDIOBOOST
Start date: March 4, 2024
Phase: N/A
Study type: Interventional

This is a multicenter prospective randomized blind controlled trial with a sham procedure group of the efficacy and safety of cardioneuroablation as a method of treating symptomatic bradycardia without a permanent pacemaker implantation

NCT ID: NCT06286540 Recruiting - Clinical trials for Aorta Thoracic; Aneurysm

Evaluation of the Efficacy and Safety of Surgical Device "Lymphoblock" for Prevention of Lymphorrhea in Patients With Thoracoabdominal Aorta Repair.

Start date: February 22, 2023
Phase: N/A
Study type: Interventional

Randomized, double-blind, placebo-controlled study will determine the clinical efficacy and safety of Lymphoblock in the prevention of postoperative retroperitoneal chylo-/lymphorrhoea in patients with open surgical treatment of the thoracoabdominal aorta. It is planned to recruit 138 clinical observations. Efficacy will be evaluated based on clinical and laboratory data.

NCT ID: NCT06286254 Active, not recruiting - Clinical trials for Acute Respiratory Viral Infection

Study of Safety and Efficacy of the Drug Cycloferone in Patients With Acute Respiratory Viral Infection

Start date: September 20, 2023
Phase:
Study type: Observational

The study will collect the information on clinical effects and safety of the basic therapy of acute respiratory viral infection (ARVI) + Cycloferone® and basic therapy of ARVI1 + Arbidol® in real-life clinical settings.

NCT ID: NCT06284265 Recruiting - Cystitis Chronic Clinical Trials

Clinical Trial of the Efficacy and Safety of Raphamin in Prevention of Recurrences of Chronic Bacterial Cystitis

Start date: October 16, 2023
Phase: Phase 3
Study type: Interventional

Clinical Trial of the Efficacy and Safety of Raphamin in Prevention of Recurrences of Chronic Bacterial Cystitis

NCT ID: NCT06281795 Recruiting - Efficacy, Self Clinical Trials

Neuromodulation of the Autonomic Nervous System in Athletes

NANSA
Start date: April 1, 2024
Phase: N/A
Study type: Interventional

There are few studies in the literature that have evaluated the effects of using percutaneous stimulation of the auricular branch of the vagus nerve for sports purposes (to accelerate recovery after physical exertion). It has been demonstrated that tVNS in athletes improved the rate of heart rate recovery, reduced lactic acid levels in blood plasma, reduced pain, reduced overtraining syndrome and fatigue levels.

NCT ID: NCT06281587 Completed - Graft Rejection Clinical Trials

Pathogenetic Risk Factors for Corneal Graft Rejection

Start date: January 2011
Phase:
Study type: Observational

There are many predictors that may influence the development of corneal graft rejection after penetrating keratoplasty. In our study investigators analysed the results of keratoplasty and the risk factors for graft rejection. Investigators analysed data from 493 patients who underwent penetrating keratoplasty between 2011 and 2019. Keratoplasty outcomes were followed up at subsequent clinic visits until December 2021. Then, 93 medical records were selected (taking into account the completeness of the medical records) and divided into two groups based on the primary diagnosis that was an indication for keratoplasty: high-risk and low-risk patients. Investigators then estimated the survival time (clear graft) of the corneal graft using Kaplan-Meier statistical survival analysis. Investigators also investigated the factors that influence corneal graft opacity.